<DOC>
	<DOCNO>NCT00745589</DOCNO>
	<brief_summary>To test hypothesis second-line fix low-dose sevelamer hydrochloride therapy effective first-line high-dose sevelamer hydrochloride therapy limit progression cardiovascular calcification .</brief_summary>
	<brief_title>Sevelamer Hydrochloride Peritoneal Dialysis Patients</brief_title>
	<detailed_description>Cardiovascular disease account nearly 50 % mortality frequent cause hospitalization ESRD patient . Hyperphosphatemia increasingly recognize important predictor mortality cardiovascular death ESRD patient largely attribute increased prevalence vascular calcification .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>ESRD patient receive longterm peritoneal dialysis treatment hyperphosphatemia currently receive aluminumbased phosphorus binder whose phosphorus control remain suboptimal calciumbased binder Patients afford selfpay sevelamer hydrochloride . Patients provide informed consent study Patients underlie active malignancy Patients cyanotic congenital heart disease Patients poor general condition Patients plan live related kidney transplant within come 1 year Female patient pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>vascular ,</keyword>
	<keyword>valvular calcification ,</keyword>
	<keyword>phosphate binder ,</keyword>
	<keyword>sevelamer ,</keyword>
	<keyword>endstage renal disease</keyword>
	<keyword>peritoneal dialysis</keyword>
</DOC>